AHR Stock Analysis: American Healthcare REIT | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 11.074m USD | 12M Return: 27.9% | US3981823038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 158M
Qual. Beats: 0
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
American Healthcare REIT, Inc. (AHR) is a Maryland-incorporated, self-managed REIT headquartered in Irvine, California. The company owns and operates a diversified portfolio of clinical healthcare real estate spanning the United States, the United Kingdom, and the Isle of Man. Its property mix includes senior housing, skilled nursing facilities (SNFs), outpatient medical (OM) buildings, and other healthcare-related assets. AHR also originates and acquires debt investments and selectively develops healthcare properties on an opportunistic basis.
The company operates senior housing under the RIDEA structure, which permits the REIT to capture both rental income and a portion of property-level operating income through a taxable REIT subsidiary (TRS). This contrasts with the traditional triple-net lease model common among healthcare REITs and typically exposes operators to direct operating risk in exchange for higher revenue participation. AHR utilizes a fully integrated management platform and has elected REIT taxation under the U.S. Internal Revenue Code, with an explicit intent to maintain compliance with applicable REIT distribution and asset requirements.
The healthcare REIT sub-industry is structurally linked to demographic aging in developed markets, which supports demand for senior housing and post-acute care facilities. International operations, such as AHRs exposure to the U.K. and Isle of Man, are relatively uncommon among U.S.-listed healthcare REITs and provide geographic diversification beyond domestic reimbursement systems like Medicare and Medicaid. AHR listed on the NYSE on February 7, 2024, and currently carries a large-cap market capitalization of roughly $11.3 billion.
- Senior housing occupancy gains drive RIDEA segment revenue growth
- Interest rate cuts ease refinancing pressure on property debt stack
- SNF Medicaid reimbursement cuts pressure skilled nursing operating margins
| Net Income: 121.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.19 > 1.0 |
| NWC/Revenue: -28.98% < 20% (prev -21.67%; Δ -7.31% < -1%) |
| CFO/TA 0.06 > 3% & CFO 369.0m > Net Income 121.0m |
| Net Debt (1.54b) to EBITDA (456.2m): 3.37 < 3 |
| Current Ratio: 0.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.7m) vs 12m ago 18.35% < -2% |
| Gross Margin: 14.94% > 18% (prev 20.62%; Δ -5.68% > 0.5%) |
| Asset Turnover: 49.01% > 50% (prev 47.70%; Δ 1.31% > 0%) |
| Interest Coverage Ratio: 2.27 > 6 (EBIT TTM 176.2m / Interest Expense TTM 77.6m) |
| A: -0.13 (Total Current Assets 156.9m - Total Current Liabilities 882.0m) / Total Assets 5.70b |
| B: -0.28 (Retained Earnings -1.60b / Total Assets 5.70b) |
| C: 0.03 (EBIT TTM 176.2m / Avg Total Assets 5.11b) |
| D: 1.88 (Book Value of Equity 3.69b / Total Liabilities 1.96b) |
| Altman-Z'' = 0.46 = B |
| DSRI: 0.88 (Receivables 229.6m/224.1m, Revenue 2.50b/2.15b) |
| GMI: 1.38 (GM 20.62% / 14.94%) |
| AQI: 0.21 (AQ_t 0.18 / AQ_t-1 0.85) |
| SGI: 1.16 (Revenue 2.50b / 2.15b) |
| TATA: -0.04 (NI 121.0m - CFO 369.0m) / TA 5.70b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of October 17, 2026, the stock is trading at USD 53.23 with a total of 2,336,839 shares traded. Over the past week, the price has changed by +4.78%, over one month by +0.65%, over three months by -5.48% and over the past year by +27.90%.
Current recommended Stop Loss: 50.80 (which is 4.6% or 2.2 ATR below the current price).
American Healthcare REIT has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy AHR.
- StrongBuy: 9
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 64.4 | 21% |
P/E Trailing = 75.8209
P/E Forward = 48.0769
P/S = 4.4212
P/B = 3.0506
Revenue TTM = 2.50b USD
EBIT TTM = 176.2m USD
EBITDA TTM = 456.2m USD
Long Term Debt = 892.7m USD (from longTermDebt, last quarter)
Short Term Debt = 549.9m USD (from shortTermDebt, last quarter)
Debt = 1.69b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.9m
Net Debt = 1.54b USD (calculated: Debt 1.69b - CCE 156.9m)
Enterprise Value = 12.6b USD (11.1b + Debt 1.69b - CCE 156.9m)
Interest Coverage Ratio = 2.27 (Ebit TTM 176.2m / Interest Expense TTM 77.6m)
EV/FCF = 48.16x (Enterprise Value 12.6b / FCF TTM 261.8m)
FCF Yield = 2.08% (FCF TTM 261.8m / Enterprise Value 12.6b)
FCF Margin = 10.47% (FCF TTM 261.8m / Revenue TTM 2.50b)
Net Margin = 4.84% (Net Income TTM 121.0m / Revenue TTM 2.50b)
Gross Margin = 14.94% ((Revenue TTM 2.50b - Cost of Revenue TTM 2.13b) / Revenue TTM)
Gross Margin QoQ = -1.04% (prev 21.30%)
Tobins Q-Ratio = 2.21 (Enterprise Value 12.6b / Total Assets 5.70b)
Interest Expense / Debt = 4.59% (Interest Expense 77.6m / Debt 1.69b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 139.2m (EBIT 176.2m * (1 - 21.00%))
Current Ratio = 0.18 (Total Current Assets 156.9m / Total Current Liabilities 882.0m)
Debt / Equity = 0.46 (Debt 1.69b / totalStockholderEquity, last quarter 3.69b)
Debt / EBITDA = 3.37 (Net Debt 1.54b / EBITDA 456.2m)
Debt / FCF = 5.86 (Net Debt 1.54b / FCF TTM 261.8m)
Total Stockholder Equity = 3.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.37% (Net Income 121.0m / Total Assets 5.70b)
RoE = 3.67% (Net Income TTM 121.0m / Total Stockholder Equity 3.29b)
RoCE = 4.21% (EBIT 176.2m / Capital Employed (Equity 3.29b + L.T.Debt 892.7m))
RoIC = 2.65% (NOPAT 139.2m / Invested Capital 5.25b)
WACC = 5.83% (E(11.1b)/V(12.8b) * Re(6.17%) + D(1.69b)/V(12.8b) * Rd(4.59%) * (1-Tc(0.21)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.03 | Cagr: 30.77%
[DCF] Terminal Value 77.97% ; FCFF base≈218.3m ; Y1≈250.3m ; Y5≈368.4m
[DCF] Fair Price = 18.38 (EV 5.54b - Net Debt 1.54b = Equity 4.01b / Shares 218.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 99.07 | Revenue CAGR: 11.31% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+3.23% | Revisions=-40% | Analysts=1
EPS current Year (2026-12-31): EPS=0.61 | Chg30d=+1.11% | Revisions=+29% | GrowthEPS=+45.5% | GrowthRev=+22.9%
EPS next Year (2027-12-31): EPS=0.99 | Chg30d=+15.12% | Revisions=+25% | GrowthEPS=+56.4% | GrowthRev=+14.7%
[Analyst] Revisions Ratio: +10% (up=4, down=3)